Earnings Call Summary | NeuroOne Medical(NMTC.US) Q4 2024 Earnings Conference
Earnings Call Summary | NeuroOne Medical(NMTC.US) Q4 2024 Earnings Conference
Forecasted revenue for fiscal year 2025 is projected between $8 million to $10 million, representing a growth of 132% to 190%.The following is a summary of the NeuroOne Medical Technologies Corporation (NMTC) Q4 2024 Earnings Call Transcript:
以下是NeuroOne医疗科技公司（NMTC）2024第四季度业绩会记录的摘要：
Financial Performance:
财务表现：
NeuroOne reported Q4 product revenue of $1.3 million, a reduction compared to the prior year, attributed to cancellation of order to transition to the new OneRF product line.
Fiscal year 2024 product revenue surged by 77% to $3.5 million.
Forecasted revenue for fiscal year 2025 is projected between $8 million to $10 million, representing a growth of 132% to 190%.
Gross margins are expected to improve in fiscal year 2025, ranging from 47% to 51% compared to 31% in 2024.
NeuroOne报告第四季度产品营业收入为130万美元，较去年下降，原因是取消订单以过渡到新的OneRF产品线。
2024财年的产品营业收入激增77%，达到350万美元。
2025财年的预测营业收入预计在800万美元到1000万美元之间，增幅为132%到190%。
预计2025财年的毛利率将改善，介于47%到51%之间，而2024年为31%。
Business Progress:
业务进展：
Successfully achieved FDA 510(k) clearance for the OneRF Ablation System and secured a strategic partnership for distribution.
Expanded partnership with Zimmer Biomet, improving distribution potential in the U.S. and certain overseas geographies.
Initiated commercialization of OneRF Ablation System with strong early adoption and interest, evidenced through completed procedures and physician training.
Pursuing additional medical applications for RF Ablation and advancing novel technologies for spinal cord stimulation and drug delivery.
成功获得OneRF消融系统的FDA 510(k)认证，并达成战略合作伙伴关系用于分销。
与Zimmer Biomet的合作关系扩大，提高了在美国和某些境外地区的分销潜力。
启动了OneRF消融系统的商业化，早期采用和兴趣强劲，通过已完成的手术和医生培训得到了证明。
正在追求RF消融的其他医疗应用，并推进脊髓刺激和药物传递的创新技术。
Opportunities:
机会：
The expanded partnership with Zimmer Biomet enhances sales proliferation and profitability.
Pursuit of new medical applications (e.g., for trigeminal neuralgia and potentially lower back and knee pain) provides competitive differentiation and potential revenue streams not currently in the 2025 guidance.
与Zimmer Biomet的扩大合作关系增强了销售的扩展和盈利能力。
追求新的医疗应用（例如，三叉神经痛以及可能的下背部和膝盖疼痛）提供了竞争差异化和潜在的营业收入来源，这些在2025年的指导中尚未体现。
Risks:
风险：
Initial slow uptake and scaling required for new medical technologies such as the OneRF Ablation System present risks to expected revenue growth.
The development and approval of new applications like for trigeminal neuralgia present uncertainties and potential delays.
对于像OneRF消融系统这样的新医疗技术，初期的缓慢采用和规模化要求给预期的营业收入增长带来了风险。
新应用程序的开发和审批，例如三叉神经痛，存在不确定性和潜在延迟。
More details: NeuroOne Medical IR
更多细节：NeuroOne 医疗投资者关系
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容的准确性无法得到完全保证。有关更全面的细节，请参考投资者关系网站。本文仅供投资者参考，不构成任何指导或建议。
